Symptoms and signs

Clearway Pain Solutions Merges with The Center for Pain

Retrieved on: 
Wednesday, June 30, 2021
Acute pain, Nervous system, Branches of biology, Symptoms and signs, Nociception, Pain management, Palliative care, Pain, Clearway

ANNAPOLIS, Md., June 30, 2021 /PRNewswire/ -- Clearway Pain Solutions has merged with The Center for Pain creating one of the largest integrated pain solutions practices in the U.S. with 40 doctors and 59 clinical practitioners serving 43 locations in Maryland, Florida, Alabama, and Delaware.

Key Points: 
  • ANNAPOLIS, Md., June 30, 2021 /PRNewswire/ -- Clearway Pain Solutions has merged with The Center for Pain creating one of the largest integrated pain solutions practices in the U.S. with 40 doctors and 59 clinical practitioners serving 43 locations in Maryland, Florida, Alabama, and Delaware.
  • "This is a celebration of two extraordinary teams joining together to bring clinical excellence to the communities of Alabama," says Clearway Pain Solutions CEO, Dr. Damean Freas.
  • Clearway Pain Solutions is the flagship brand with the corporate headquarters in Annapolis, MD.
  • Dr. Freas also explained that the broader Clearway Pain Solutions platform is good for those needing a trusted practice to send patients in need of specialized pain management.

Sense Relief Receives Grant From UCSF-Stanford Pediatric Device Consortium for Further Development and Study of the Treatment for Pregnancy Related Nausea and Vomiting

Retrieved on: 
Monday, June 28, 2021
Vomiting, Digestive diseases, Symptoms and signs, Clinical medicine, Nausea, Antiemetics, Ketones, 5-HT3 antagonists, Oncology

SAN FRANCISCO, June 28, 2021 /PRNewswire/ --Sense Relief, Inc. received an innovation grant from the UCSF-Stanford Pediatric Device Consortium for the continued technical development and further clinical study of Sense Relief, an antiemetic digital therapeutic.

Key Points: 
  • SAN FRANCISCO, June 28, 2021 /PRNewswire/ --Sense Relief, Inc. received an innovation grant from the UCSF-Stanford Pediatric Device Consortium for the continued technical development and further clinical study of Sense Relief, an antiemetic digital therapeutic.
  • The study will help determine the efficacy of this novel health wearable treatment method, understand usage patterns, and classify the causes of nausea, such as medication-induced nausea, stress-related nausea, and vestibularneuritis.
  • The technical development of Sense Relief will integrate CardinalKit to support an ongoing consumer study of thousands of Sense Relief users.
  • The Sense Relief app is available for download to the Apple Watch to help ease symptoms of nausea.

A Performance and Lifestyle Brand For Ambitious Individuals

Retrieved on: 
Friday, June 25, 2021
Acute pain, Nervous system, Branches of biology, Symptoms and signs, Psychological stress, Pain, Enhancement

The brand has positioned itself as a healthy, effective option for ambitious individuals who aren't just looking for stress relief and pain management.

Key Points: 
  • The brand has positioned itself as a healthy, effective option for ambitious individuals who aren't just looking for stress relief and pain management.
  • Remedy+ has chosen to focus on formulations and methods that lend themselves to personal enhancement.
  • This approach is aptly summarized in in the brand's tag line, "Relax.
  • These products genuinely enhance an individual's ability to perform throughout the day by providing solid nutritional support, mental clarity, and robust levels of stamina.

June is Migraine and Headache Awareness Month

Retrieved on: 
Wednesday, June 23, 2021
Migraine, Symptoms and signs, Neurological disorders, Medicine, Aura, Headache, Acephalgic migraine, Messoud Ashina

"I get nausea both from my migraine aura and from the extreme pain of the migraines themselves," says one migraine patient who suffers from migraine-related nausea.

Key Points: 
  • "I get nausea both from my migraine aura and from the extreme pain of the migraines themselves," says one migraine patient who suffers from migraine-related nausea.
  • According to the Migraine Research Foundation, migraine affects approximately 39 million men, women, and children in the United States and 1 billion worldwide.
  • "We're proud to support the American Migraine Foundation in helping to raise awareness for Migraine and Headache Awareness Month," Nihan says.
  • Learn more about Migraine and Headache Awareness Month at americanmigrainefoundation.org .

Global Pain Management Drugs Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 23, 2021
Health, Pharmaceutical, Nervous system, Branches of biology, Acute pain, Symptoms and signs, Pain, Palliative care, Nociception

The "Pain Management Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pain Management Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global pain management drugs market reached a value of US$ 74 Billion in 2020.
  • Looking forward, the publisher expects the global pain management drugs market to exhibit moderate growth during the forecast period (2021-2026).
  • Pain management drugs perform pharmacological actions on pain receptors and work against discomfort-causing symptoms.

CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms

Retrieved on: 
Monday, June 21, 2021
Medicine, Health sciences, Clinical medicine, Leronlimab, Symptoms and signs, Long Covid, Malaise, Placebo

Chris Recknor, M.D., CytoDyns Chief Operating Officer and Head of Clinical Development, commented, We are very pleased with the preliminary results from our long-haulers trial, which showed a greater improvement in the leronlimab patient group over placebo in 18 of 24 COVID-19 symptoms.

Key Points: 
  • Chris Recknor, M.D., CytoDyns Chief Operating Officer and Head of Clinical Development, commented, We are very pleased with the preliminary results from our long-haulers trial, which showed a greater improvement in the leronlimab patient group over placebo in 18 of 24 COVID-19 symptoms.
  • Of the remaining 6 symptoms, sore throat, exertional malaise, anxiety, nausea, and vomiting had no clinically meaningful change.
  • In my opinion, our hypothesis that leronlimab is an immune modulator has received a very positive boost from this trial.
  • This trial will evaluate the effect of leronlimab on clinical symptoms and laboratory biomarkers to further understand the pathophysiology of PASC.

OliPass Expands Scientific Advisory Board by Inviting Experts in Pain To Bolster Phase 2 Clinical Trial Design and Management

Retrieved on: 
Thursday, June 10, 2021
Nervous system, Branches of biology, Symptoms and signs, Pain, Nociception, Acute pain, Neuropathic pain, Peripheral neuropathy

Professor Dougherty and Professor Dworkin will advise OliPass on Phase 2 clinical trials of OLP-1002.

Key Points: 
  • Professor Dougherty and Professor Dworkin will advise OliPass on Phase 2 clinical trials of OLP-1002.
  • Considering the pharmacological complexity of neuropathic pain, however, expertise in neuropathic pain and in clinical study design will be critical to a success in the clinical development of OLP-1002 against neuropathic pain.
  • We are very much honored to have Professor Dougherty and Professor Dworkin as new SAB members as we develop the first-in-class pain killer.
  • He has significantly contributed to defining mechanism of cancer therapy-induced pain and identifying potential therapeutic interventions for its relief or prevention.

Migraine and Headache Awareness Month: gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Treats & Prevents Migraine and Cluster Headaches

Retrieved on: 
Tuesday, June 8, 2021
General Health, Health, Other Health, Medical devices, Headaches, Symptoms and signs, Medicine, Clinical medicine, Trigeminal autonomic cephalgia, Migraine, Medication overuse headache, Hemicrania continua, Cluster headache, Headache, International Classification of Headache Disorders, NIH classification of headaches, electroCore, Inc, gammaCore, ELECTROCORE, INC, GAMMACORE

Successful treatment with gammaCore may generate savings for patients and provide overall benefit by preventing attacks, reducing pain intensity and frequency.

Key Points: 
  • Successful treatment with gammaCore may generate savings for patients and provide overall benefit by preventing attacks, reducing pain intensity and frequency.
  • gammaCore may also help reduce medical costs for migraine including frequent doctors visits and pharmaceuticals or other treatments.
  • The companys current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.
  • gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches

Retrieved on: 
Monday, June 7, 2021
FDA, General Health, Pharmaceutical, Health, Medicine, Symptoms and signs, Branches of biology, Headaches, Migraine, Pain management, Cluster headache, Autoinjector, Headache, Aura

If approved, Amneal anticipates a commercial launch in the second half of 2022.

Key Points: 
  • If approved, Amneal anticipates a commercial launch in the second half of 2022.
  • The proposed indication for the product is acute migraine with and without aura and cluster headache in adults.
  • This product would allow patients to self-administer DHE via a single-dose, ready-to-use autoinjector pen without the need for assembly.
  • Over 39 million Americans are living with migraine(1), and up to one million with cluster headache.

Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers

Retrieved on: 
Friday, June 4, 2021
Pain, Palliative care, Agnosía, Analgesic, Opioids, Pain management, Nervous system, Branches of biology, Symptoms and signs

Nutra Pharma is announcing the first private label agreement in expansion of their line of over-the-counter pain relievers and anti-inflammatory drugs

Key Points: 
  • The first private label distributor contract has been executed with sales expected to start within the next 4-6 weeks.
  • "This will allow increased sales to Nutra Pharma by expanding our customer base into markets not currently available to us.
  • Nyloxin is a safe, non-narcotic, and non-addictive Homeopathic pain reliever for the relief of pain without impairing cognitive function.
  • Nyloxin is available as an oral spray for systemic pain and as a topical gel for targeted pain management.